Prevention and treatment of urinary retention and infection after surgical treatment of the colon and rectum with alpha adrenergic blockers.
In a retrospective study, 153 male patients who underwent surgical treatment of the colon and rectum presented with complaints indicating obstruction of the prostate gland and clear indications for preoperative administration of alpha-blockers. Between the years 1982 and 1984, the alpha-blocker phenoxybenzamine hydrochloride (PB-HCl) was prohibited from use by the Ministry of Health because of suspicions of its carcinogenic properties. This enabled a comparative study between two groups of patients. Seventy-five patients (group 2a1) were prohibited from receiving PB-HCl. Urinary retention occurred in 54.7 per cent and urinary tract infection in 65.3 per cent. Seventy-eight patients (group 2a2) were administered PB-HCl. In this group of patients, urinary retention occurred in 19.2 per cent and urinary tract infection in 15.4 per cent. Forty-one patients with urinary retention of group 2a1 who were not administered PB-HCl were compared with 50 patients with urinary retention (group 3) who received PB-HCl. Spontaneous relief was observed in 21.9 and 76.0 per cent, respectively. PB-HCl was shown to be extremely effective, both as a preventative and therapeutic agent, when complaints indicating the prostate gland are present in patients undergoing surgical treatment of the colon and rectum.
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D003106:Colon / Q000601:surgery*; D006801:Humans; D008297:Male; D010643:Phenoxybenzamine / Q000627:therapeutic use*; D011183:Postoperative Complications / Q000517:prevention & control*; D012007:Rectum / Q000601:surgery*; D012189:Retrospective Studies; D014552:Urinary Tract Infections / Q000517:prevention & control*; D014555:Urination Disorders / Q000517:prevention & control*
D000317:Adrenergic alpha-Antagonists; D010643:Phenoxybenzamine